Metabolic Disorders - Page 1
Stay up to date with the latest Metabolic Disorders updates from the global drugdevelopment industryLatest Metabolic Disorders Update
Sucampo Pharmaceuticals has announced the pooled data from post-hoc analyses of the two pivotal Phase 3 studies of Amitiza (lubiprostone), used for the treatment of irritable bowel syndrome...
> read more
Achaogen plazomicin drug meets Phase 2 study endpoints
Achaogen's plazomicin (ACHN-490) drug has met all the objectives in the multinational Phase 2 study conducted in adults with complicated urinary tract infections (cUTI) and acute...
Scil Proteins, Ono Pharmaceutical enter into drug discovery alliance
Germany-based biotech company, Scil Proteins, has entered into a joint collaboration agreement with Japan's Ono Pharmaceutical for the discovery and development of new Affilin therapeutics to...
Diltiazem hydrochloride cream shows improvement over placebo in study
Ventrus Biosciences has reported positive data from a Phase 3 study treating patients suffering from anal fissures with its diltiazem hydrochloride cream (VEN...
Cytochroma CTAP101 capsules show efficacy in Phase 2b study
Cytochroma has announced the positive results from the Phase 2b clinical trial of its drug product, CTAP101 capsules, used for the treatment of patients with secondary hyperparathyroidism...
Alnylam reports Phase 1 data of ALN-TTR01 drug
Alnylam Pharmaceuticals has announced the final results from its completed Phase 1 clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of...
Novartis pasireotide drug found superior to standard therapy
Novartis has reported results from a Phase 3 study that reveal that pasireotide (SOM230) long-acting release (LAR) was effective at inducing full biochemical control compared to current...
Tolero partners with MannKind to develop BTK inhibitors
Tolero Pharmaceuticals has signed a licence agreement with MannKind to develop and commercialise Bruton's tyrosine kinase (BTK) inhibitors for the treatment of haematological malignancies...
MHRA launches new strategy to tackle counterfeit medicines
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new three-year anti-counterfeiting strategy, the Falsified Medical Products Strategy 2012 - 2015, which...
Vyvanse drug meets Phase 2 study endpoints: Shire reports
Shire, a specialty biopharmaceutical company, has reported the positive data from the Phase 2 study of its Vyvanse (lisdexamfetamine dimesylate) capsules, (CII) in adults with binge eating...
EU clears Novartis Signifor drug for Cushing's disease
Switzerland-based Novartis International has received European Union (EU) approval for its Signifor (pasireotide) drug, used as a medication to treat adult patients with Cushing's disease for...
Alnylam ALN-PCS found to lower LDL cholesterol: Phase I study
Alnylam Pharmaceuticals has reported positive clinial results from a Phase I study of ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), for the...
Biodel reports positive Phase I RHI trial data
Biodel has reported positive top-line data from a Phase I trial of its ultra-rapid-acting formulations of recombinant human insulin (RHI), BIOD-123 and...
Opko Health begins Phase 3 trials of Rolapitant drug
Opko Health is enrolling patients in the Phase 3 clinical programme for Rolapitant, designed for the prevention of chemotherapy induced nausea and vomiting...
UK to open applications for Biomedical Catalyst fund soon
The £180m Biomedical Catalyst fund from the UK government will open for applications by the end of this...
URMC, Temple University invest in drug discovery programme
The University of Rochester Medical Center (URMC) and the Moulder Center for Drug Discovery Research at Temple University, US, have jointly invested $500,000 in the Drug Discovery Pilot...
GSK reports Albiglutide data from Phase lll studies
GlaxoSmithKline (GSK) has achieved topline results from seven of the eight Harmony Phase III studies investigating the use of albiglutide in patients with type 2...
Shire reports Phase 3 results of ulcerative colitis drug
Shire has announced the results from the Phase 3 PREVENT2 trial of its once-daily SPD476, MMX mesalamine in ulcerative colitis patients with a history of...
NGM partners with Daiichi Sankyo to develop diabetic therapies
Daiichi Sankyo and NGM Biopharmaceuticals have entered into a research collaboration and licence agreement to discover and develop therapeutics that modulate beta-cell regeneration for...
AMT reports positive data from Glybera study
Amsterdam Molecular Therapeutics (AMT) has announced the positive data from Glybera 14 week study demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec)...
Targacept announces TC-6987 data from Phase 2 trials
Targacept, a clinical-stage biopharmaceutical company, has reported the data from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in asthma and type 2...
